ONCO Share Price Performance
Recent ONCO News & Updates
No updates
Onco-Innovations Limited Key Details
Last Reported Earnings
Apr 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0012
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Onco-Innovations Limited Competitors
About ONCO
- Founded
- n/a
- Employees
- 1
- CEO
- WebsiteView website
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
Canadian Market Performance
- 7 Days: 0.9%
- 3 Months: 11.7%
- 1 Year: 17.4%
- Year to Date: 10.1%
The Consumer Staples sector gained 3.6% while the market remained flat over the last week. As for the longer term, the market has risen 17% in the past 12 months. Earnings are forecast to grow by 12% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
